Brief: Ssy Group Says Letter Of Intent In Relation To License Of Class 1 Innovative Drug Opt101
15/06/2026 02:41
BRIEF-Ssy Group Says Letter Of Intent In Relation To License Of Class 1 Innovative Drug Opt101 June 15 (Reuters) - SSY Group Ltd 2005.HK:
LETTER OF INTENT IN RELATION TO LICENSE OF CLASS 1 INNOVATIVE DRUG OPT101
UNIT ENTERED INTO A LETTER OF INTENT WITH OPTERION HEALTH AG
LOI IN RELATION TO RESEARCH, DEVELOPMENT, OTHERS IN RESPECT OF OPT101
Further company coverage: 2005.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on SSY
See all newsBrief: SSY Group Receives NMPA China Approval For Sodium Cromoglicate Eye Drops 2%
Brief: SSY Group Obtains NMPA Approval For Nimodipine Oral Solution
Brief: SSY Group Appoints Wu Heng Yao As Executive Director
Brief: SSY Group Says Ziprasidone Mesilate Receives Registration Approval In China
Hong Kong's SSY Group H1 profit rises on infusion solutions growth